Kyntra Bio, Inc. (KYNB)

NASDAQ: KYNB · USD

$4.60

+0.10 (+2.2%)· Recorded snapshot

Market cap	18.6M
Revenue (ttm)	4.6M
Net income (ttm)	183.2M
EPS (ttm)	$45.3
Shares out	4M
P/E (trailing)	0.1x
Volume	12,864
Beta	1.05

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 4.6M
Net income (ttm): 183.2M
EPS (ttm): $45.3
P/E (trailing): 0.1x
Market cap: 18.6M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Manter

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/E0.1

P25 15.4P50 25.8P75 43.5

ROEn/a

P25 -113.8P50 -46.5P75 -0.9

ROIC-68.6

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All KYNB indicators

Market & fundamental data

Available fields

192

Groups with data

Currency

USD

Showing 192 of 192 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000921299
Company name	Kyntra Bio, Inc.
Country	United States
Country code	US
CUSIP number	31572Q881
Earnings date	2026-11-09
Earnings time	amc
Employees	34
Employees change	-191
Employees growth	-84.89%
Enterprise value	$-72.7M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1993
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US31572Q8814
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split date	2025-06-17
Last stock split type	Reverse
Market cap	$18.6M
Market cap category	Nano-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$4.60
Price currency	USD
Sector	Healthcare
Stock price date	2026-10-28
Symbol	KYNB
U.S. state	California
Website	https://www.kyntrabio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	0.12x
Earnings yield	984.05%
FCF / EV yield	52.42%
FCF yield	-203.46%
Forward P/S	2.73x
P/E ratio	0.1x
P/S ratio	4.05x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Operating margin	-1,088.56%
Pretax margin	-669.71%
Profit margin	3,968.63%
Profit per employee	$5.4M
Profitable quarters	1
Profitable years	1
Revenue per employee	$135,765
ROA	-22.5%
ROA (5Y)	-27.5%
ROCE	-77.26%
ROIC	-68.57%
SBC / revenue	86.35%
Tax / revenue	-0.02%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	3
Net income growth quarters	1
Net income growth years	3
Revenue growth	-37.16%
Revenue growth 10Y	-29.92%
Revenue growth 3Y	-67.18%
Revenue growth 5Y	-51.49%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-9,000
Depreciation and amortization	$213,000
EBIT	$-50.2M
EBITDA	$-50M
EPS	$45.27
FCF per share	$-9.40
Financing cash flow	$-85.9M
Free cash flow	$-38.1M
Free cash flow minus SBC	$-42M
Gross profit	$-22.6M
Income taxes	$-1,000
Investing cash flow	$56.1M
Net borrowing	$-80.6M
Net cash flow	$-69.2M
Net income	$183.2M
Operating cash flow minus SBC	$-42M
Operating income	$-50.2M
Revenue	$4.6M
Stock-based compensation	$4M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-24.36
Book value per share	$-7.44
Interest coverage	-5.41
Long-term assets	$4.3M
Long-term liabilities	$73.2M
Net cash (debt)	$91.3M
Net cash / market cap	488.15%
Piotroski F-Score	3
Shareholders' equity	$-8.1M
Tangible book value	$-30.1M
Tangible book value per share	$-7.44
Total assets	$101.1M
Total cash	$91.3M
Total debt	$0
Total liabilities	$109.2M
WACC	10.04%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.03
Current assets	$96.8M
Current liabilities	$36M
Current ratio	2.69
Inventory turnover	7.5
Net working capital	$-30.5M
Quick ratio	2.54
Working capital	$60.8M
Working capital turnover	0.14

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-0.32%
Dividend yield	0%
Shareholder yield	-0.32%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-98.87%
10Y return CAGR	-36.11%
10Y total return	-98.87%
150-day SMA	$6.96
1D price change	2.22%
1M price change	-33%
1M total return	-33%
1W price change	-11.93%
1W total return	-11.93%
1Y price change	-58.18%
1Y return CAGR	-58.21%
1Y total return	-58.18%
20-day SMA	$5.50
200-day SMA	$7.15
3M price change	-34.04%
3M total return	-34.04%
3Y price change	-60.93%
3Y return CAGR	-26.89%
3Y total return	-60.93%
50-day SMA	$6.79
50-day SMA vs 200-day SMA	50under200
52-week high	$11.39
52-week high date	2025-11-07
52-week low	$4.32
52-week low date	2026-10-27
5Y price change	-98.26%
5Y return CAGR	-55.53%
5Y total return	-98.26%
6M price change	-33.85%
6M total return	-33.85%
All-time high	$1,713.75
All-time high date	2018-07-09
All-time low	$4.32
All-time low date	2026-10-27
Average true range (ATR)	$0.38
Average volume	23.8K
Beta (1Y)	1.36
Beta (2Y)	0.69
Beta (5Y)	1.05
Change from 52-week high	-59.61%
Change from 52-week low	6.48%
Change from all-time high	-99.73%
Change from all-time low	7.64%
Change from open	0%
Day's gap	2.22%
Dollar volume	$59,174
High price	$4.60
Low price	$4.60
Monthly RSI	33.58
Open price	$4.60
Previous close	$4.50
Price vs 150-day SMA	-33.15%
Price vs 20-day SMA	-15.49%
Price vs 200-day SMA	-34.96%
Price vs 50-day SMA	-31.49%
Relative volume	0.54
RSI	26.68
Sharpe ratio	-1.41
Sharpe ratio (3Y)	0.21
Sharpe ratio (5Y)	-0.17
Sortino ratio	-1.85
Sortino ratio (3Y)	0.39
Sortino ratio (5Y)	-0.19
Volume	12.9K
Weekly RSI	30.44
YTD price change	-47.04%
YTD total return	-47.04%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	3.6M
Float percentage	88.08%
Shares change (QoQ)	0.02%
Shares change (YoY)	0.32%
Shares held by insiders	2.04%
Shares held by institutions	12.88%
Shares outstanding	4M
Short % of float	2.81%
Short % of shares	2.47%
Short ratio	3.9 days

Deeper analysis on KYNB

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this KYNB report

Is a complete KYNB research report available?

No complete published report is available for Kyntra Bio, Inc. (KYNB) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Kyntra Bio, Inc. (KYNB)

Price

Financial snapshot

Fair-value bridge

Latest news · KYNB

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All KYNB indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on KYNB

Frequently asked questions